57543-71-2

Basic information

• Product Name: 6-METHOXY-2H-CHROMENE-3-CARBONITRILE
• Synonyms: 6-methoxy-2h-1-benzopyran-3-carbonitril;6-METHOXY-2H-CHROMENE-3-CARBONITRILE;6-Methoxy-2H-1-benzopyran-3-carbonitrile
• CAS NO: 57543-71-2
• Molecular Formula: C₁₁H₉NO₂
• Molecular Weight: 187.19
• Mol File: 57543-71-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 75°
• Boiling Point: 75°C
• Flash Point: 141.1°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 7.2E-05mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 6-METHOXY-2H-CHROMENE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-2H-CHROMENE-3-CARBONITRILE(57543-71-2)
• EPA Substance Registry System: 6-METHOXY-2H-CHROMENE-3-CARBONITRILE(57543-71-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 57543-71-2(Hazardous Substances Data)

Usage

General Description

6-METHOXY-2H-CHROMENE-3-CARBONITRILE is a chemical compound with the molecular formula C10H7NO3. It is a nitrile derivative of 2H-chromene, and it contains a methoxy group at the 6th position. 6-METHOXY-2H-CHROMENE-3-CARBONITRILE is used in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and pharmaceutical products due to its unique chemical structure and properties. Additionally, it may also have other industrial applications, but further research and testing are necessary to fully understand its potential uses.

InChI:InChI=1/C11H9NO2/c1-13-10-2-3-11-9(5-10)4-8(6-12)7-14-11/h2-5H,7H2,1H3

Upstream product

• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 107-13-1 acrylonitrile 
• 280-57-9 1,4-diaza-bicyclo[2.2.2]octane 

Downstream Products

• 182570-26-9 6-methoxy-3,4-dihydro-2H-1-benzopyran-3-carboxylic acid 
• 182570-28-1 (S)-6-methoxychroman-3-carboxylic acid 
• 1094472-13-5 SR 3850 
• 57543-40-5 6-methoxy-2H-chromene-3-carbaldehyde 
• 76322-25-3 6-methoxychroman-3-one 
• 203987-26-2 3-aminomethyl-6-methoxy-3,4-dihydro-2H-1-benzopyran 
• 57543-62-1 3-caboxy-6-methoxy-2H-1-benzopyran 

Relevant articles and documents

Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors

ROCK1 and ROCK2 are highly homologous isoforms. Accumulated studies indicate that they have distinct different functions, and the development of isoform selective ROCK inhibitors will pave new roads for the treatment of various diseases. In this work, a series of amide-chroman derivatives were synthesized and biologically evaluated in order to develop potent and isoform selective ROCK2 inhibitors. Remarkably, (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide ((S)-7c) possessed ROCK2 inhibitory activity with an IC50 value of 3 nM and 22.7-fold isoform selectivity (vs. ROCK1). Molecular docking indicated that hydrophobic interactions were the key element for the high potency and isoform selectivity of (S)-7c. The binding free energies predicted by MM/GBSA were in good agreement with the experimental bioactivities, and the analysis of individual energy terms suggested that residue Lys105 in ROCK1 or Lys121 in ROCK2 was the key residue for the isoform selectivity of (S)-7c.

Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists

Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine, has been regarded as a potential target for the treatment of various metabolic diseases, cancer and infectious diseases related to liver. Starting from two previously identified chalcone-based FXR antagonists, we tried to increase the activity through the design and synthesis of a library containing chalcones, flavones and chromenes, based on substitution manipulation and conformation (ring closure) restriction strategy. Many chalcones and four chromenes were identified as microM potent FXR antagonists, among which chromene 11c significantly decreased the plasma and hepatic triglyceride level in KKay mice.

Substituted heterocyclic compounds, method for preparing and compositions containing same

The invention relates to compounds of formula (I): wherein: R1, R2and R3are as defined in the description, X is as defined in the description, Y represents an oxygen atom, a sulphur atom, a C(H)qgroup, SO or SO2, n is equal to from 0 to 5, A represents a NR5R6group, and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.